L-Cysteine methyl ester hydrochloride (CAS 18598-63-5), C₄H₉NO₂S·HCl, molecular weight 171.65 g mol⁻¹, is supplied as a white to off-white crystalline solid in which the carboxyl terminus is blocked as a methyl ester and the amino function is protonated by hydrogen chloride. The salt form reduces zwitterionic character relative to L-cysteine free base, raises solubility in polar aprotic solvents such as dimethylformamide and dimethyl sulfoxide, and provides a defined stoichiometric counterion for gravimetric charging in peptide synthesis. Commercial material is commonly offered in reagent grade at ≥98.0% HPLC area and in synthesis grade at ≥99.0% with the D-enantiomer limited to ≤0.5%. Loss on drying ≤0.50% after vacuum drying at 60°C for 4 h, residue on ignition ≤0.10%, and heavy metals ≤10 mg kg⁻¹ are typical release criteria; however, limits should be verified against the supplier’s certificate of analysis because no harmonised pharmacopoeial monograph applies universally to this derivative. Bulk stability is controlled by storing the powder in amber glass under nitrogen at 2–8°C, with pre-drying recommended when ambient relative humidity exceeds 60% RH before gravimetric batch charging.

Product model nomenclature is supplier-specific rather than a unified international code. Typical catalogue designations encode the L-enantiomer, the methyl ester, and the hydrochloride salt; the purchaser must confirm whether the listed material is the hydrochloride salt or the free base, and whether the methyl ester is the L- or DL-form. Synonyms include H-Cys-OMe·HCl, methyl L-cysteinate hydrochloride, and (2R)-2-amino-3-sulfanylpropanoic acid methyl ester hydrochloride.

A saturated aqueous solution at 20°C is clear and colourless at 100 g L⁻¹; the substance is freely soluble in methanol and dimethylformamide, sparingly soluble in ethyl acetate, and practically insoluble in hexane. Aqueous solutions are acidic, with a 1% solution pH typically between 1.5 and 2.5 due to the hydrochloride salt. Neutralisation with organic bases liberates the free amino ester; under these conditions the thiol should be regarded as oxygen-sensitive.

What Limits Free-Thiol Stability in Aqueous Processing?

The dominant degradation path is oxidative dimerisation of the thiol to L-cystine dimethyl ester dihydrochloride. The rate is pH-dependent because the thiolate anion is a far stronger nucleophile toward dissolved oxygen than the protonated thiol. At pH 4.5–6.0, aqueous process solutions under a nitrogen atmosphere are generally stable over a working shift at 20–25°C; above pH 8.0, discoloration and dimer formation can occur within hours in air-saturated media. Iron and copper ions catalyse the autoxidation, so glass or glass-lined reactors rather than unlined stainless steel, and the addition of edetate disodium at 0.1 mM where formulation permits, are common controls.

Hydrolysis of the methyl ester competes with oxidation at pH extremes. Strongly acidic conditions below pH 2.0, particularly above 40°C, generate free L-cysteine hydrochloride and methanol. Conversely, alkaline conditions above pH 9.0 accelerate saponification and concurrently oxidise the thiolate; the two degradation routes make aqueous handling above pH 9.0 unsuitable for retention of the blocked C-terminus. A practical processing window is therefore pH 3.5–6.5 at temperatures not above 30°C for periods under 8 h. Where extended hold times are unavoidable, the solution should be kept at 1–5°C and sparged with nitrogen through a 0.22 μm filter. Published data for this specific configuration is limited; the boundaries are drawn from supplier stability protocols rather than a formal ICH guideline.

Production-scale dissolution in peptide coupling campaigns commonly uses a jacketed glass-lined reactor with bottom drain, a nitrogen sparge ring, and a PTFE dip tube. The agitator is configured for low-shear circulation, typically 50–100 rpm for a 100–500 L vessel, to avoid vortex entrainment of air. Batch-to-batch variance in thiol titre is controlled by pre-reaction assay using reversed-phase HPLC at 210 nm rather than by weight alone because retained moisture or dimer impurity can shift the effective thiol concentration.

Reactivity Differences Across Cysteine Derivatives

The methyl ester hydrochloride differs from L-cysteine hydrochloride monohydrate in that the C-carboxyl is blocked; from N-acetyl-L-cysteine in that the N-terminus remains available; and from L-cysteine ethyl ester hydrochloride in the ester alkyl chain length. These differences alter solubility, reaction scope, and side-product profile.

The methyl ester is selected over L-cysteine hydrochloride monohydrate when the C-terminal carboxyl must not participate in activation. In carbodiimide-mediated couplings the free acid can form mixed anhydrides and presents a competing electrophilic centre, whereas the methyl ester remains a passive ester. This removes a competing electrophilic centre and reduces the requirement for highly controlled stoichiometry of the coupling reagent. The ethyl ester is preferred when a longer ester alkyl group is needed to moderate release rate of the liberated alcohol in subsequent saponification or to increase reversed-phase retention time; the additional methylene unit also increases lipophilicity and can reduce aqueous dissolution rate under identical pH conditions. N-Acetyl-L-cysteine differs fundamentally because the amino group is blocked; it is therefore appropriate as a thiol donor or antioxidant in formulations, but it cannot serve as a C-terminal protected amino acid in peptide coupling without a deacetylation step. The enantiomeric D-form has identical molecular weight but reversed optical rotation. It is not a drop-in substitute for L-peptide synthesis; residual D-isomer is measured by chiral HPLC against a specification limit rather than inferred from total assay.

When L-Cysteine Methyl Ester Hydrochloride Replaces Free Cysteine in Solution-Phase Peptide Coupling

Solution-phase manufacture of C-terminal cysteine peptides frequently uses this compound as the C-blocked amino component. In a typical campaign, the hydrochloride is suspended in anhydrous dimethylformamide at 0–5°C and neutralised in situ with 1.0–1.05 eq of N-methylmorpholine or diisopropylethylamine before an activated N-protected amino acid is added. Coupling reagents in common use include HATU, HBTU, or EDCI with ethyl cyano(hydroxyimino)acetate; the choice is determined by the tendency of the activated species to racemise at the cysteine α-carbon. Preactivation of the acid component at 0°C for 3–5 min followed by addition of the neutralised methyl ester reduces base-mediated racemisation and thiolate formation. Off-gassing from the neutralisation is managed by a nitrogen sweep.

Process bottlenecks on larger scale include local pH excursion during base addition, which can cause dimerisation before coupling. Metered addition of base through a mass-flow-controlled dosing pump, with in-line pH measurement between 3.5 and 5.5, is used to avoid a localised alkaline plume. Agitation is maintained at 80–120 rpm in a 50 L glass-lined reactor to ensure rapid micro-mixing without gas entrainment. After coupling, the product is isolated by extraction into ethyl acetate or precipitation into cold diethyl ether; the methyl ester remains intact for downstream C-terminal deprotection by saponification with lithium hydroxide in tetrahydrofuran–water at 0–5°C. The hydrolysis of the methyl ester is considerably faster than that of the ethyl ester, which can be advantageous where a rapid deprotection step is required; published kinetic data for this specific substrate under production conditions are limited.

Residual solvent profiles after drying are typically controlled for methanol, ethyl acetate, diethyl ether, and dimethylformamide. Headspace gas chromatography with flame ionisation detection, using a DB-624 capillary column or equivalent, is the common release method. Methanol is of particular concern because it can be generated by ester hydrolysis during storage or processing. A limit of ≤3,000 mg kg⁻¹ methanol is commonly set for synthesis-grade material, while pharmaceutical intermediate buyers may require ≤500 mg kg⁻¹ depending on the final drug product and ICH Q3C residual solvent classification. Batching under nitrogen and avoiding acidic aqueous workups above 25°C are the primary controls for methanol generation.

Specification and Release Testing Under Pharmacopoeial Alignment

Because this derivative is not the subject of a dedicated monograph in Ph. Eur. or USP, release testing is assembled from general methods. Infrared identification is performed against a qualified reference standard using a KBr pellet; the carbonyl stretch for the methyl ester appears in the region 1740–1750 cm⁻¹, distinct from the carboxylate band of L-cysteine hydrochloride. Assay by HPLC uses a C18 column, 5 μm particle size, 250 × 4.6 mm, with a phosphate buffer–acetonitrile mobile phase at pH 3.0 and UV detection at 210 nm. Chiral purity is determined separately by ligand-exchange HPLC or derivatisation with Marfey’s reagent; a limit of ≤0.5% D-enantiomer is typical for synthesis-grade material. Heavy metals by ICP-MS after microwave digestion are limited to ≤10 mg kg⁻¹, and residual solvents by headspace GC follow ICH Q3C options. Release testing is performed under the supplier’s ISO 9001 quality system; analytical methods are qualified in accordance with ICH Q2(R1).

Thiol content can be titrated by Ellman’s reagent spectrophotometric assay at 412 nm; this is used in production to normalise batch-to-batch variation. Calibration against freshly prepared L-cysteine hydrochloride standards is run daily because the reagent blank drifts under ambient light. The HPLC assay is preferred for release because it resolves the methyl ester hydrochloride, free cysteine, and the cystine dimer.

In downstream pharmaceutical formulations, L-cysteine methyl ester hydrochloride has been examined as a cysteine prodrug because the ester neutralises the carboxylic acid charge and may improve passage across lipid membranes. Aqueous hydrolysis to cysteine and methanol occurs readily in plasma esterase-containing media, but published human pharmacokinetic data for this derivative are limited; therefore, the developer must generate compartment-specific hydrolysis profiles under the intended formulation pH and buffer system rather than relying on surrogate data from the free amino acid. In such work, the hydrochloride salt should be handled with the same thiol-antioxidant controls as described for peptide coupling, and the final formulation should be tested for cysteine and methanol content under ICH stability conditions.

Bulk packaging for 25 kg fibre drums with double low-density polyethylene liners and silica gel sachets is common at reagent scale; for synthesis-grade material in quantities above 50 kg, high-density polyethylene containers under nitrogen with a tamper-evident seal are used. In both cases, the headspace oxygen should be below 5%. Cold-chain transport at 2–8°C is specified for intercontinental shipments lasting more than 72 h. At receiving, the material should be quarantined and sampled under low-humidity conditions; if the container interior exceeds 25°C or the desiccant indicator exceeds 40% RH, the lot should be examined for hydrolysed cysteine and dimer content before release.

Regulatory documentation supplied with the product should include a Safety Data Sheet compliant with REACH Annex II and, where applicable, a registration number for the substance. No harmonised occupational exposure limit is assigned specifically to L-cysteine methyl ester hydrochloride; the dust should be controlled below the applicable nuisance particulate limit in the production jurisdiction. The material is incompatible with oxidising agents such as hydrogen peroxide or hypochlorite and should not be combined with alkaline amine solutions without first controlling dissolved oxygen and temperature, because thiolate oxidation and ester base hydrolysis occur simultaneously.